IMV Inc.
OTC: IMVIF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Andrew Hall
- Employees
- 63
- Headquarters
- Dartmouth, Canada
- IPO year
- 2013
- Market cap
- $23.4K
- Website
- https://www.imv-inc.com
Loading IMVIF…
Loading profile data…Frequently asked questions about IMVIF
What does IMV Inc. (IMVIF) do?
IMV Inc. is a biopharmaceutical firm focused on immuno-oncology, currently in the clinical development stage. The company leverages its proprietary DPX immune-modulating platform to create a diverse range of treatments aimed at both solid tumors and blood cancers. The flagship therapeutic, maveropepimut-S, is an immunotherapy derived from the DP...
Where does IMVIF trade?
IMV Inc. (IMVIF) trades on the Other OTC.
What sector is IMVIF in?
IMV Inc. (IMVIF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of IMV Inc.?
Andrew Hall is the chief executive officer of IMV Inc. (IMVIF).
Where is IMV Inc. headquartered?
IMV Inc. is headquartered in Canada.
Does IMVIF pay a dividend?
IMV Inc. (IMVIF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMVIF go public?
IMV Inc. (IMVIF) completed its initial public offering in 2013.